Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Advanced Solid Tumors with Abnormal Hippo Signaling Pathway

被引：0
|
作者：
Zhao, Kehao
Zhag, Yong
Shi, Yufang
Chen, Jian
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB428
引用
收藏
页数：2
相关论文
共 7 条
  • [1] The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment
    Santucci, Matteo
    Vignudelli, Tatiana
    Ferrari, Stefania
    Mor, Marco
    Scalvini, Laura
    Bolognesi, Maria Laura
    Uliassi, Elisa
    Costi, Maria Paola
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (12) : 4857 - 4873
  • [2] Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling
    Zhao, Bin
    Pobbati, Ajaybabu. V. V.
    Rubin, Brian. P. P.
    Stauffer, Shaun
    PHARMACEUTICALS, 2023, 16 (04)
  • [3] Discovery of BPI460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations
    Shen, Hongling
    Xu, Xiaofeng
    Rong, Hongfei
    Song, Xizhen
    Gao, Jinheng
    Chen, Jie
    Zhu, Di
    Zhao, Xiangdong
    Tong, Jun
    Zou, Zhengyao
    Liu, Xiaoyun
    Guo, Jin
    Xu, Yan
    Li, Yabin
    Liu, Xiangyong
    Chen, Hong
    Zhao, Jiayu
    Liu, Yanju
    Ju, Xuepeng
    Chen, Haibo
    Lan, Hong
    Ding, Lieming
    Wang, Jiabing
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Hot Spot Analysis of YAP-TEAD Protein-Protein Interaction Using the Fragment Molecular Orbital Method and Its Application for Inhibitor Discovery
    Kim, Jongwan
    Lim, Hocheol
    Moon, Sungho
    Cho, Seon Yeon
    Kim, Minhye
    Park, Jae Hyung
    Park, Hyun Woo
    No, Kyoung Tai
    CANCERS, 2021, 13 (16)
  • [5] Discovery of a first-in-class TEAD inhibitor which directly inhibits YAP/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma
    Kaneda, Ayumi
    Seike, Toshihiro
    Uemori, Takeshi
    Myojo, Kensuke
    Aida, Kensuke
    Danjo, Tomohiro
    Nakajima, Takahiro
    Yamaguchi, Daisuke
    Hamada, Tomoko
    Tsuji, Yoshiro
    Hamaguchi, Kaori
    Yasunaga, Mai
    Otsubo, Nobumasa
    Onodera, Hideyuki
    Nishiya, Yoichi
    Suzuki, Michihiko
    Saito, Junichi
    Ishii, Toshihiko
    Nakai, Ryuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [6] First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
    Perez Garcia, Jose Manuel
    Cortes, Javier
    Stathis, Anastasios
    Mous, Rogier
    Lopez-Miranda, Elena
    Azaro, Analia
    Genta, Sofia
    Nuciforo, Paolo
    Vivancos, Ana
    Ferrarotto, Renata
    Bertoni, Francesco
    Rossi, Davide
    Burr, Nicole Spardy
    Schonborn-Kellenberger, Oliver
    Jorga, Karin
    Beni, Laura
    Lehal, Rajwinder
    Bauer, Michael
    Weber, Dirk
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
    Yap, Timothy A.
    Kwiatkowski, David J.
    Desai, Jayesh
    Dagogo-Jack, Ibiayi
    Millward, Michael
    Kindler, Hedy L.
    Tolcher, Anthony W.
    Frentzas, Sophia
    Thurston, Archie W.
    Post, Len
    Dorr, F. Andrew
    CANCER RESEARCH, 2023, 83 (08)
1